Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs > .50/.60 cents Friday
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by ama21968on Oct 07, 2010 8:39pm
219 Views
Post# 17543186

RE: .50/.60 cents Friday

RE: .50/.60 cents FridaySorry, I don't think so, because:

#1: Tomorrow is Friday and long weekend for Canadian markets, I really hope Halo has a sharp pull back, If so tomorrow will be a BUY!!

#2: I think this week run up is so called " test run" for market makers, It will have a PULL BACK to test mid 30's (I really hope)... Market makers need to " shake" "wash out " as many retial investors as possible. as there are too many RATs accounts bought cheap shares at 25 - 30's.

50's is a wall in short term !!!  

Mettest  results is a ? Insider option price is ? .

I would not buy at recent "high" I know it is still undervalued here, but  definitely WATCH CAREFULLY!!! QUICK HANDS ON THE BUY SIDE IF PULL BACK!!!

My bet is tomorrow Friday before long weekend, there r no highlights for the day and markets on both sides, very low volume, no directions...  Pepple leave early for TURKEY !!!!

We will see! Cash is ready

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities